Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
April 25 2008 - 5:05PM
PR Newswire (US)
SAN DIEGO, April 25 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the
Morgan Stanley Global Healthcare Unplugged Conference in Key
Biscayne, FL on Thursday, May 1, 2008 at 9:20 a.m. ET / 6:20 a.m.
PT. Daniel M. Bradbury, President and Chief Executive Officer of
Amylin Pharmaceuticals, will be providing a corporate overview. The
live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcast
and recording will be accessible through Amylin's corporate
website, located at http://www.amylin.com/. To access the live
webcast, please log on to Amylin's site approximately fifteen
minutes prior to the presentation to register and download any
necessary audio software. About Amylin Pharmaceuticals Amylin
Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and
commercialization of innovative medicines. Amylin has developed and
gained approval for two first-in-class medicines for diabetes,
SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)
injection. Amylin's research and development activities leverage
the company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California with over 1,900 employees nationwide. Further
information on Amylin Pharmaceuticals is available at
http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc.
CONTACT: Michael York, Senior Director, Investor Relations of
Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024